ABSTRACT
Corona viral disease was first recorded in 2019 in China and WHO named as COVID-19 disease. It affect the humanmainly causes the Respiratory tract infection related symtoms[2,3]. COVID-19 not only affect the respiratory tract, gastro intestinal tract and other system also to be affected. Corona virus affect the not only the humans, animals also to be affected [4]. The Shenbaga Poo Kuligai is one of the Siddha Drug classically used in treatment of Mantham in pediatric age group. The term Mantham used in Siddha System, to mention group of Gastro intestinal disorder in Childrens and adults. The drug Shenbaga poo kuligai well treated the symptoms of SuzhiManthamclinically. Suzhimantham is Respiratory disesease followed by Gastro intestinal disorder in Childrens.So,auther decided to molecular docking study inShenbaga poo kuligai in the treatment of Noval Corona Viral disease caused bySARS CoV-2to identifify the Phyto chemical components and inhibitors to the main protease to the viruses by Computerized molecular Docking.There are 8 phyto components identified namelyGallic acid, Costunolide, Thymol, Nerolidol, Glabridin, Glycyrrhizin, s-vetivone, Limoneneand used to Docking.The Ligands showing least binding energyareGlycyrrhizin-9.51 kcal/mol, Glabridin-7.52 kcal/mol, Nerolidol-6.32 kcal/mol.These binding energies shows efficient Docking of Shenbaga poo kuligai and inhibition of the viral main Protease. Binding of phytocomponents with the core amino acids (Leu 27, His 41, Gly 143, Cys 145, His 163, His 164, Met 165, Glu 166, Pro 168, His 172) of the target by forming hydrogen bond will hinder the function of the target COVID-19 main protease [3-chymotrypsin-like protease (3CL pro) ]- PDB- 6LU7 is considered to be the potential target as it is highly essential for cleavage of polyprotein to get16 nonstructural proteins (called nsp1-nsp16). These non-structural proteins are highly essential for viral replication and survival[1]. Thereby phytocomponents which inhibit the target 3CL pro enzyme may act as a potential therapeutic agent for management of COVID-19 and related symptoms. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
ABSTRACT
As per world health organization report on 23 December 2022,there are 6.5 million confirmed cases of covid -19 which include 6.6 lacks deaths.[1] In current scenario new drug desining for covid -19 is essential and molecular docking study of spike protein SARS CoV-2 with human ACE2 molecules help to new Drug designing for corona virus.[2]According to siddha principle and medicine all disease can be treated successfully. The Research study of the Drug Shenbaga poo kuligai show good result in the treatment of SuzhiMantham[3]. The term SuzhiMantham in Siddha aspect, indicate the symptoms of Pain full and Spasmodic breathing[9] and the suzhimantham symptoms correlated to Acute Nasopharyngitis and WALRI in Children[6].The siddha Drug shenbaga poo kuligai will effectively treat the covid _ 19 Symptoms of Nasal discharge, Nasal obstruction, Fever, Difficulty in breathing, Rib Retraction, Cough, Wheezing, Pallorness of the body, Loss of appetite these are all also Suzhimantham symptoms[3-5] In the Molecular Docking study binding of phytocomponents of Shenbaga poo kuligai with the core amino acids of the target by forming hydrogen bond will hinder the function of the target COVID-19 spike glycoprotein with receptor-binding domain - PDB 6VSB is considered to be the potential target as it is highly essential to initiate the process of ACE2 recognition, binding and facilitate the entry of virus in to the host cell. Thereby phytocomponents Shenbaga poo kuligai that reveals potential binding with active amino acid on the receptor-binding domain of novel corona virus may act as a potential therapeutic agent for management of COVID-19 and related symptoms. All herbs in shenbaga poo kuligai is easily available and it was safe to covid patient. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
ABSTRACT
Background: Cancer patients are at increased risk of infection due to immunosuppression, poor nutrition, and other health problems. Various studies have shown that cancer patients have a higher risk of serious complications related to Coronavirus disease (COVID-19) than patients without cancer, however, the strength of associated varied significantly across the studies. We aim to analyze the differences in the clinical characteristics, laboratory parameters, and hospital outcomes of COVID-19 among patients with and without cancer. Method(s): This was a retrospective study of 1873 patients including 102 cancer patients who presented with SARS-CoV-2 infection at our hospital. Our primary outcome was the in-hospital mortality rate due to COVID-19 and the secondary outcome was a comparison of demographic, clinical, laboratory, and treatment parameters of cancer patients compared to non-cancer patients. Multivariate logistic regression models were fitted to identify factors predictive of disease progression in the hospital, including death. Result(s): Cancer patients had a higher in-hospital mortality rate than non-cancer patients (26.5 vs 21.2 %, P=0.211). The proportion of people with anemia, thrombocytopenia, and leukopenia was significantly higher in the cancer group. The median value of inflammatory markers (ferritin, D-dimer, and IL-6) in the cancer group is approximately two times than non-cancer group. The odds of worsening [1.73 (1.01-2.95)] and death [2.83 (1.46-5.47)] during hospital stay were significantly higher in cancer patients. Hematological malignancies had higher odds of developing critical illness [4.96 (1.57-15.7)] and receiving mechanical ventilation [4.35 (1.27-15.0)] compared to non-cancer cases. In cancer patients, breathlessness and hypoxia at presentation were significant predictors of mortality when adjusted for other clinical features. Conclusion(s): Cancer patients with COVID-19 infection have abnormally high inflammatory responses compared with non-cancer patients and the development of breathlessness and hypoxia are important predictors of mortality. Patients with hematological malignancies have a higher risk of developing serious disease. Legal entity responsible for the study: The authors. Funding(s): Has not received any funding. Disclosure: All authors have declared no conflicts of interest. Copyright © 2022
ABSTRACT
Background: Governments have imposed lockdowns in the wake of the COVID-19 pandemic. Hospitals have restricted outpatient clinics and elective services meant for non-COVID illnesses. This has led to patients facing unprecedented challenges and uncertainties. This study was carried out to assess patients' concerns and apprehensions about the effect of the lockdown on their treatments. Materials and Methods: An ambispective, observational cross-sectional single centre study was conducted. Patients were contacted telephonically and requested to answer a structured questionnaire. Their responses were documented and summarized as frequency and proportions. Results: A total of 727 patients were interviewed. Epilepsy (32%) was the most common neurological illness in our cohort followed by stroke (18%). About half the patients and/or their caregivers reported health-related concerns during the lockdown. The primary concern was how to connect with their treating neurologist if need arose. Forty-seven patients (6.4%) had drug default. Among patients on immunomodulatory treatments, only eight patients had drug default. High compliance rates were also observed in the stroke and epilepsy cohorts. Of the 71 patients who required emergency care during the lockdown, 24 could reach our hospital emergency. Fourteen patients either had a delay or could not seek emergency care. Two-thirds of our patients found the telemedicine experience satisfactory. Conclusion: The ongoing pandemic will continue to pose challenges to both physicians and patients. Patients in follow-up may need to be contacted regularly and counselled regarding the importance of maintaining drug compliance. Telemedicine can be used to strengthen the healthcare delivery to patients with non-COVID illnesses.
ABSTRACT
BACKGROUND AND PURPOSE: Occurrence of stroke has been reported among patients with COVID-19. The present study compares clinical features and outcomes of stroke patients with and without COVID-19. METHODS: The COVID-19 Stroke Study Group (CSSG) is a multicentric study in 18 sites across India to observe and compare the clinical characteristics of patients with stroke admitted during the current pandemic period and a similar epoch in 2019. The present study reports patients of stroke with and without COVID-19 (CoVS and non-CoVS, respectively) seen between February 2020 and July 2020. Demographic, clinical, treatment, and outcome details of patients were collected. RESULTS: The mean age and gender were comparable between the two groups. CoVS patients had higher stroke severity and extent of cerebral involvement on imaging. In-hospital complications and death were higher among CoVS patients (53.06% vs. 17.51%; P < 0.001) and (42.31% vs. 7.6%; P < 0.001), respectively. At 3 months, higher mortality was observed among CoVS patients (67.65% vs. 13.43%; P < 0.001) and good outcome (modified Rankin score [mRS]: 0-2) was seen more often in non-CoVS patients (68.86% vs. 33.33%; P < 0.001). The presence of COVID-19 and baseline stroke severity were independent predictors of mortality. CONCLUSIONS: CoVS is associated with higher severity, poor outcome, and increased mortality. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and baseline stroke severity are independent predictors of mortality.